Skip to main content
Contribution to Book
Small-Molecule Inhibitors Reveal a New Function for Bcl-2 as a Pro-angiogenic Signaling Molecule
Small-Molecule Inhibitors of Protein-Protein Interactions
  • Benjamin David Zeitlin, University of the Pacific
  • Jacques E. Nör, University of Michigan School of Dentistry
ORCID
Dr. Benjamin D. Zeitlin: 0000-0003-0110-0188
Department
Biomedical Sciences
Document Type
Contribution to Book
Editor(s)
Lyubomir Vassilev and David Fry
Description

Cancer has a complex etiology and displays a wide range of cellular escape pathways that allow it to circumvent treatment. Signaling molecules functionally downstream of the circumvented pathways, and particularly at checkpoints where several of these pathways intersect, provide valuable targets for the development of novel anti-cancer drugs. Bcl-2, a pro-survival signaling molecule, is one such protein. This review examines the efficacy, potency, and function of several small molecule inhibitor drugs targeted to the Bcl-2 family of proteins. The review focuses on the compounds with most available data within the literature and discusses both the anti-cancer and the recently unveiled anti-angiogenic potential of this new class of drugs.

ISBN
978-3-642-17083-6
Publication Date
1-1-2011
Publisher
Springer
Comments
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 348)
Citation Information
Benjamin David Zeitlin and Jacques E. Nör. "Small-Molecule Inhibitors Reveal a New Function for Bcl-2 as a Pro-angiogenic Signaling Molecule" Small-Molecule Inhibitors of Protein-Protein Interactions (2011) p. 115 - 137
Available at: http://works.bepress.com/benjamin-zeitlin/39/